title: Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats.
abstract: We investigated the role of hypothalamic insulin signaling in the regulation of energy balance and insulin action in rats through selective decreases in insulin receptor expression in discrete hypothalamic nuclei. We generated an antisense oligodeoxynucleotide directed against the insulin receptor precursor protein and administered this directly into the third cerebral ventricle. Immunostaining of rat brains after 7-day administration of the oligodeoxynucleotide showed a selective decrease of insulin receptor protein within cells in the medial portion of the arcuate nucleus (decreased by approximately 80% as compared to rats treated with a control oligodeoxynucleotide). Insulin receptors in other hypothalamic and extra-hypothalamic areas were not affected. This selective decrease in hypothalamic insulin receptor protein was accompanied by rapid onset of hyperphagia and increased fat mass. During insulin-clamp studies, physiological hyperinsulinemia decreased glucose production by 55% in rats treated with control oligodeoxynucleotides but by only 25% in rats treated with insulin receptor antisense oligodeoxynucleotides. Thus, insulin receptors in discrete areas of the hypothalamus have a physiological role in the control of food intake, fat mass and hepatic action of insulin.
authors.affiliation: Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York 10461, USA.
authors.forename: Silvana
authors.initials: S
authors.lastname: Obici
authors.forename: Zhaohui
authors.initials: Z
authors.lastname: Feng
authors.forename: George
authors.initials: G
authors.lastname: Karkanias
authors.forename: Denis G
authors.initials: DG
authors.lastname: Baskin
authors.forename: Luciano
authors.initials: L
authors.lastname: Rossetti
mesh_terms: D000273:Adipose Tissue / Q000473:pathology; D054369:Agouti-Related Protein; D000818:Animals; D001111:Arcuate Nucleus of Hypothalamus / Q000378:metabolism; D004435:Eating; D005947:Glucose / Q000096:biosynthesis; D006963:Hyperphagia / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism*; D007276:Injections, Intraventricular; D007328:Insulin / Q000097:blood / Q000378:metabolism / Q000494:pharmacology; D007333:Insulin Resistance / Q000502:physiology*; D036341:Intercellular Signaling Peptides and Proteins; D008099:Liver / Q000187:drug effects; D008297:Male; D009478:Neuropeptide Y / Q000378:metabolism; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000494:pharmacology; D011506:Proteins / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011972:Receptor, Insulin / Q000037:antagonists & inhibitors* / Q000235:genetics
chemical_list: D054369:Agouti-Related Protein; D007328:Insulin; D036341:Intercellular Signaling Peptides and Proteins; D009478:Neuropeptide Y; D016376:Oligonucleotides, Antisense; D011506:Proteins; D011972:Receptor, Insulin; D005947:Glucose